Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...